## RARE: Ultragenyx Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.4% in lower entry zone (4.0-10.0%), top quartile (89th pct) cross-sectional ranking. Short-term MRS_5 (2.7%) confirms momentum alignment. Strong momentum (+5.5% 5-day acceleration). Outperforming sector by 8.7%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($33.28)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 4
- **Sentiment:** Bearish (Bullish: 0, Bearish: 0)

**1. Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by Sands Capital Management LLC**
- Source: MarketBeat | 20251205T042432 | Somewhat-Bearish | Relevance: 100%
- Sands Capital Management LLC reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 5.3% in the second quarter, selling over 220,000 shares. This comes as Ultragenyx missed quarterly earnings and revenue estimates, reporting a negative EPS of ($1.81) against an expected ($1.23). Despite the financial performance, Wall Street maintains a "Moderate Buy" consensus rating with an average target price of $80.23, although some analysts have recently lowered their targets.

**2. Schroder Investment Management Group Acquires 71,888 Shares of Ultragenyx Pharmaceutical Inc. $RARE**
- Source: MarketBeat | 20251205T042432 | Somewhat-Bearish | Relevance: 100%
- Schroder Investment Management Group significantly increased its stake in Ultragenyx Pharmaceutical Inc. by 27.2% during the second quarter, now holding 336,173 shares valued at approximately $12.22 million. Despite this institutional confidence, the biopharmaceutical company recently missed EPS estimates and has seen some insider selling. Wall Street analysts currently rate RARE as a "Moderate Buy" with an average target price of $80.23, although some have recently cut their price targets.

**3. Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue?**
- Source: Yahoo Finance | 20251204T103000 | Somewhat-Bearish | Relevance: 100%
- Ultragenyx (RARE) shares have increased by 14.4% since its last earnings report, outperforming the S&P 500. Despite missing Q3 2025 earnings and sales estimates, the company reported a 15% year-over-year revenue increase and reaffirmed its 2025 financial guidance. Investors are now watching if this positive trend will continue given downward revisions in analyst estimates.

**4. Skandinaviska Enskilda Banken AB publ Has $2.46 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE**
- Source: MarketBeat | 20251203T130921 | Somewhat-Bearish | Relevance: 100%
- Skandinaviska Enskilda Banken AB publ significantly increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 108.1% in the second quarter, now owning 67,720 shares valued at approximately $2.46 million. Other institutional investors also boosted their holdings, with institutional ownership of Ultragenyx now standing at about 97.67%. Despite a "Moderate Buy" consensus rating and an average price target of $80.23, Ultragenyx recently missed Q3 earnings and revenue estimates, and its stock trades well below the target at around $33.37.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.36M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-0.8%)
- JPMORGAN CHASE & CO: 8.3% (+146.0%)
- FMR, LLC: 7.6% (+179.6%)
- Blackrock Inc.: 6.7% (+2.7%)
- Sands Capital Manage: 3.9% (-4.4%)

### Key Risks

1. Elevated short interest (9.2%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +5.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Revenue growth strong at 21% YoY. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.3B |
| Beta | 0.16 |
| 52W Range | $25.81 - $46.50 |
| Short Interest | 9.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.24 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from 0.9% to 6.4% (+5.5% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 89th percentile. MRS_5 at 2.7% confirms short-term momentum alignment. AM_20 at 8.9% shows strong absolute momentum above own 20MA. Outperforming sector by 8.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.43% (CS: 89) | Strong |
| RSI_14 | 62.8 | Neutral |
| MACD Histogram | 0.37 | Bullish |
| vs SMA20 | 1.089x | Above |
| vs SMA50 | 1.109x | Above |
| vs SMA200 | 1.073x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $36.38
- **Stop Loss:** $33.28 (8.5% risk)
- **Target:** $41.03 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 161
- **Position Value:** $5,857.18
- **Portfolio %:** 5.86%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-12 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.21 | $-1.81 | -49.7% |
| 2025Q2 | $-1.32 | $-1.17 | +11.4% |
| 2025Q1 | $-1.64 | $-1.57 | +4.4% |
| 2024Q4 | $-1.27 | $-1.39 | -9.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*